Natera Inc (NTRA)
Natera, Inc. is a biotechnology company focused on the development and commercialization of molecular diagnostic testing services in global markets. Its menu of products includes Signatera for minimal residual disease assessment and treatment monitoring in cancer, Latitude for colorectal cancer MRD testing, Altera for comprehensive genomic profiling, and Empower for hereditary cancer screening. The company also provides reproductive and prenatal testing such as Panorama, Horizon, Fetal Focus, Vistara, and Anora, along with Prospera for transplant rejection assessment and Renasight for kidney gene panel testing. Natera supports its customers through services and platforms including Constellation software, NateraCore, phlebotomy services, and EMR integration. The company works with laboratories, medical centers, physician practices, research laboratories, and pharmaceutical companies, and it has a partnership with BGI Genomics for NGS-based genetic testing assays. Founded in 2003 and headquartered in Austin, Texas, Natera is listed on NASDAQ as common stock.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-NTRA
|
$202.82
|
-45.1% Downside
|
Overvalued
|
$344.33
|
-6.8% Downside
|
Fair
|
Great
|
0.0%
|
November 11, 2026
|
29.2x
|
19.7x
|
53.245 B
|
52.392 B
|
0.4%
|
97.1%
|
37.4
|
-43.8%
|
